NCEL.US NewcelX Ltd.

Healthcare Biotechnology USA Stocks
2.61 USD
Close of Nov 15, 2026
1.83 5.12
Market cap
USD 15.1M
P/E
5.0x
P/B
2.46x
ROE
47.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is NCEL.US undervalued?

Graham number
Price2.61
Graham value3.52
Discount25.9%

NCEL.US trades 25.9% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NewcelX Ltd. fundamental analysis

No fundamental analysis for NewcelX Ltd. yet.

NewcelX Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NewcelX Ltd.

NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Ag…

Full company profile